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Small   molecules   can   be   physicochemically   targeted   to   mitochondria   using   the  
lipophilic   alkyltriphenylphosphonium   (TPP)   group.   Once   in   the   mitochondria   the  
TPP-­‐‑conjugate   can   detect   or   influence   processes   within   the   mitochondrial   matrix  
directly.    Alternatively,  the  conjugate  can  behave  as  a  prodrug,  which  is  activated  by  
release   from   the  TPP  group   either   using   an   internal   or   external   instruction.      Small  
molecules  can  be  designed  that  can  be  used  in  any  cell  line,  tissue  or  whole  organism,  
allow  temporal  control,  and  be  applied  in  a  reversible  dose-­‐‑dependent  fashion.     An  
example  is  the  detection  and  quantification  of  hydrogen  peroxide  in  mitochondria  of  
whole   living   organisms   by   MitoB.   Hydrogen   peroxide   produced   within   the  
mitochondrial   matrix   is   involved   in   signalling   and   implicated   in   the   oxidative  
damage   associated   with   aging   and   a   wide   range   of   age-­‐‑associated   conditions  
including  cardiovascular  disease,  neurodegeneration  and  cancer.  MitoB  accumulates  
in  mitochondria  and  is  converted  into  the  exomarker,  MitoP,  by  hydrogen  peroxide  
in   the  mitochondrial   matrix.      The   hydrogen   peroxide   concentration   is   determined  
from   the   ratio   of   MitoP   to   MitoB   after   a   period   of   incubation,   and   this   ratio   is  
determined   by   mass   spectrometry   using   d15-­‐‑MitoP   and   d15-­‐‑MitoB   as   standard.    
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Here  we   describe   the   synthesis   of  MitoB   and  MitoP   and   the   deuterated   standards  
necessary  for  this  method  of  quantification.  
  
1.  Introduction  
1.1  Mitochondria-­‐‑targeted  drugs  and  prodrugs  
Small   molecule   drugs   are   vital   to   medicine   (1).      They   can   often   be   administered  
orally,   and   produce   rapid   dose-­‐‑dependent   effects.      Similarly,   small   molecules   are  
useful   tools   to   the  molecular   biologist   seeking   to   elucidate   biological   processes.   A  
key  advantage  to  small  molecules  is  that  in  theory  they  can  be  used  in  any  cell  line,  
tissue,   organ  or   organism.  Their  use  does  not   require   the  manipulation  of  proteins  
and  gene  expression  through  mutation  and  RNA-­‐‑dependent  gene  silencing,  so  they  
can  be  applied  to  native  tissues  and  organisms.  Furthermore,  a  small  molecule  that  is  
useful   for   the  study  of  a  biological  process  can  often  be  a   lead  compound   for  drug  
discovery,  and  vice  versa.      
Mitochondria  play  a   central   role   in  metabolism,   supplying  most  of   the  ATP  
used  by  cells,  and  also  are  key  to  signalling,  homeostasis,  and  the  events  leading  up  
to   apoptosis   and   necrosis   (2,3).      Mitochondrial   dysfunction   contributes   to   almost  
every   age-­‐‑associated   disease   including   cardiovascular   diseases,   neurodegeneration  
and  cancer  (2),  and  is  implicated  in  the  process  of  aging  itself  (4,5).  
Drugs  can  act  on  targets  in  the  mitochondria  without  having  an  independent  
mechanism  for  their  accumulation  there.    However,  efficacy  would  be  increased  and  
side-­‐‑effects  decreased  if  the  concentration  of  a  drug  is  elevated  near  its  site  of  action.    
For   this   reason,   it   is  desirable   to  have  a  mechanism  of   targeting  small  molecules   to  
the   mitochondria,   and   in   particular   the   mitochondrial   matrix   where   much   of  
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metabolism  is  sited.    Fortunately,  there  are  a  variety  of  approaches  for  the  delivery  of  
molecular  cargo  to  mitochondria  (6).  These  include  liposomes  (7,8),  nanoparticles  (9),  
and   peptide   sequences   (10),   but   the   most   general   method   of   delivery   involves  
conjugating   the   small  molecule   to   a   lipophilic   delocalized   cation   (3).   The   targeting  
takes   advantage   of   the   membrane   potential   across   the   mitochondrial   inner  
membrane  (MIM).      
The  electron  transport  chain  (ETC)  sited  in  the  MIM  pumps  protons  out  of  the  
mitochondrial   matrix   into   the   intermembrane   space   between   the   MIM   and   the  
mitochondrial   outer  membrane.      This   gives   rise   to   a   small   difference   in   pH   and   a  
high   membrane   potential   due   to   charge   separation   across   the   MIM,   because   the  
positively   charged   protons   are   not   accompanied   by   anions.      Thus,   the   membrane  
potential  (Δψ)  across  the  MIM  is  negative  on  the  matrix  side.    A  proton-­‐‑motive  force  
resulting  from  the  membrane  potential  and  to  a  lesser  extent  the  pH  gradient  drives  
the  production  of  ATP  from  ADP  and  phosphate  by  ATP-­‐‑synthase.      
Targeting   to   the   mitochondrial   matrix   can   be   achieved   by   incorporating   a  
lipophilic  cation  in  the  drug  (Figure  2).     Lipophilic  cations  can  cross  the  MIM  freely  
by  diffusion  both  in  and  out.     The  positive  charge  leads  to  accumulation  within  the  
mitochondrial  matrix  as  a  result  of  the  membrane  potential.    The  process  is  governed  
by  the  Nernst  equation  so  that  for  every  60  mV  there  is  a  ten-­‐‑fold  accumulation  in  the  
matrix   relative   to   the   cytosol.      This   results   in   a   several-­‐‑hundred-­‐‑fold   higher  
concentration  in  the  matrix  for  a  membrane  potential  between  120-­‐‑180  mV.    There  is  
also   a   small   plasma  membrane   potential   that   leads   to   a   3-­‐‑10   fold   accumulation   of  
lipophilic   cations  within   the   cell,   and   this  means   that   the   concentration  within   the  
mitochondrial  matrix  may  be  over  a  thousand-­‐‑fold  that  outside  the  cell.  
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It   is   important   to   note   that   the   individual   lipophilic   cations   are   continually  
freely  diffusing  in  and  out  of  the  mitochondria.    If  such  diffusion  is  implausible  due  
to   size,   e.g.   some   nanoparticles   may   be   too   large   to   cross   the   MIM   (11),   then   an  
alternative   explanation   for   accumulation   is   necessary   and   the   specific   localization  
within   the   mitochondria   needs   to   be   elucidated.   Furthermore,   the   higher  
concentration  within  the  matrix  does  not  cancel  the  charge  inside;  the  overall  ratio  is  
maintained   by   the  membrane   potential   and   is   independent   of   the   concentration   of  
lipophilic  cation  used,  e.g.  a  300:1  ratio  would  be  maintained  if  it  were  300  nM  :  1  nM  
or  if  it  were  3  µμM  :  10  nM.  
The   lipophilic   cation   of   choice   is   the   alkyltriphenylphosphonium   (TPP)  
cation3   because   it   has   been   extensively   validated   in   vivo,   including   in   humans,   e.g.  
volunteers   in   a   phase   II   clinical   trial   of   MitoQ   were   dosed   orally   with   this  
mitochondria-­‐‑targeted   antioxidant   for   1   year   without   safety   issues   (12)   (Figure   1).    
Conjugates   of   TPP   diffuse   freely   across  membranes   and   the   cationic   nature   of   the  
compounds   gives   them   good   water-­‐‑solubility.      TPP   is   shaped   like   an   inside-­‐‑out  
umbrella  and  so  does  not   intercalate   into  DNA,  which  can  be  a  problem  for  planar  
lipophilic  cations  such  as  phenanthridinium  ions  (13).  The  TPP  group  is  small  and  so  
it   does   not   adversely   affect   the   physicochemical   properties.      It   is   also   easily  
introduced  by  chemical  synthesis  (see  below).    
A   wide   range   of   TPP-­‐‑conjugates   have   been   synthesized   and   shown   to  
accumulate  in  mitochondria  (Figure  1).    Generally,  the  cargo  molecule  is  not  charged,  
but   carboxylic   acids   that   exist   predominantly   in   their   anionic   carboxylate   form   at  
pH7  can  be  targeted  to  mitochondria  using  TPP.      Indeed,  zwitterionic  carboxylate  1  
accumulates  to  a  greater  extent  than  the  simple  triphenylmethylphosphonium  cation.    
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At   first   sight   this   may   seem   perplexing   as   the   zwitterion   1   has   no   overall   charge  
(Figure  3)   (14).  The  key   feature  of   this   system   is   that   the  zwitterionic   form  1   is   too  
polar   to  cross  membranes  but   it   is   in  equilibrium  with   the  monocationic  carboxylic  
acid   2,   which   is   a   lipophilic   cation   and   can   diffuse   freely   across   the   MIM.      The  
carboxylic  acid  form  2  partitions  across  the  membrane  in  accordance  with  the  Nernst  
equation.      The   carboxylic   acid   2   inside   the   matrix   is   also   in   equilibrium  with   the  
deprotonated  membrane-­‐‑impermeant  zwitterion  1.      If   the  pH  were  the  same  on  the  
inside  and  outside  of  the  MIM,  the  zwitterionic  form  1  would  accumulate  to  the  same  
degree  as   the  carboxylic  acid  2.     However,   the  pH   inside   is  higher   than  outside,   so  
accumulation  of  the  zwitterionic  form  inside  is  greater  than  would  be  expected  from  
the  Nernst  equation  alone.  
The   TPP-­‐‑conjugate   could   be   a   drug   itself,   as   is   the   case   of  MitoQ   (15)   and  
most  other  drug  candidates  that  use  the  TPP  targeting  group  (Figure  4a).    In  theory  a  
TPP-­‐‑drug  would  distribute  throughout  the  body,  concentrating  in  tissues  with  high  
mitochondrial  content,  such  as  muscle  and  liver.     However,  what  if  selectivity  for  a  
single   tissue  or   site   is   important?      In   these   cases   a  prodrug   strategy   is   appropriate  
whereby   the   inactive   prodrug   distributes   to   all   mitochondria,   but   the   drug   is  
released  from  the  TPP  targeting  group  only  within  particular  mitochondria  or  inside  
the  mitochondria  of  particular  tissues.      
Prodrug  activation  could  either  be  by  an   instruction   from  outside   the   living  
cells   (Figure  4b)  or  by  a  process  within   the  mitochondria   (Figure  4c),   and  we  have  
demonstrated  both  approaches   (16,17).     MitoPhotoDNP   (17)   is  a  UV   light-­‐‑activated  
mitochondrial  uncoupler   (Figures  1d  and  4b).   It  accumulates   in  all  mitochondria   in  
accordance   with   the   Nernst   equation,   but   can   be   activated   within   particular  
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mitochondria   by   irradiation   with   UV   light   to   release   the   proton   translocator,   2,4-­‐‑
dinitrophenol  (DNP).    DNP  crosses  the  MIM  in  both  its  protonated  phenol  form  and  
its  deprotonated  phenoxide  form  (DNP–),  and  so  it  abolishes  the  membrane  potential  
of   the   selected   mitochondria,   uncoupling   the   electron-­‐‑transport   chain   from   ATP-­‐‑
synthase.    This  gives  sustained,  but  localized  disruption  of  mitochondrial  function.      
Each  cell  contains  many  mitochondria  and  it  is  likely  that  some  function  well,  
while  others  are  dysfunctional.    The  production  of  reactive  oxygen  species  (ROS)  as  a  
result  of  reduction  of  oxygen  to  superoxide  by  complex  I  of  the  ETC  in  particular,  is  
implicated   in   the   process   of   ageing   and   age-­‐‑related   diseases   (Figure   5)   (18-­‐‑21).  
Reverse   electron   transport   through   the   ETC   contributes   to   the   production   of  
superoxide   and   is   greatest   when   the  membrane   potential   is   high   (22).   Superoxide  
rapidly   disproportionates   to   hydrogen   peroxide   and   molecular   oxygen   under  
catalysis   from   superoxide   dismutase   (SOD),   and   elevated  mitochondrial   hydrogen  
peroxide  levels  appear  to  contribute  to  the  aged  phenotype.  Indeed,  the  free  radical  
theory   of   ageing   suggests   that   mitochondrial   ROS   are   the   main   driving   force   of  
ageing.   It  may  be   tempting   to   suggest   that   antioxidants  would   slow   the  process  of  
ageing   and   provide   a   panacea   for   the   treatment   of   diseases   where   damage   is  
mediated  or  accentuated  by  oxidative  stress.  However,  this  has  not  proved  to  be  the  
case  (23),  possibly  because  the  antioxidants  are  not  distributing  to  the  regions  where  
they   are   needed.      Non-­‐‑targeted   antioxidants   may   also   interfere   with   intracellular  
signalling,  which  is  partly  mediated  by  hydrogen  peroxide  and  other  ROS.      
Targeting  antioxidants   to   the  mitochondria  ameliorates  oxidative  damage  at  
the   site   where   most   endogenous   ROS   are   generated.      Thus,   the   TPP-­‐‑antioxidant  
conjugates  MitoQ  (15),  MitoE  (24),  and  the  various  TPP-­‐‑nitroxide  conjugates  (25-­‐‑28)  
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are   effective   antioxidants   that   scavenge   ROS   (Figures   1a   and   4a);   some   of   these  
require  in  situ  reduction  to  generate  the  active  antioxidant  and  this  provides  a  route  
for  regeneration.    Thus,  even  though  they  react  stoichiometrically,  each  molecule  can  
quench  many  ROS  as  a  result  of  recycling.  MitoQ  is  an  example  of  this:  it  is  activated  
as   an   antioxidant   by   reduction   by   the   ETC   within   the   mitochondria,   is   rapidly  
reactivated  after  oxidation  by  ROS  (29).  Mechanistic  mimetics  of  SOD  and  peroxidase  
have   also   been   targeted   to  mitochondria   (Figure   1b)   (28,30,31);   although   these   are  
true   catalysts,   their   turnover   rates   are   significantly   slower   than   endogenous  
enzymes.     On  the  other  hand,   the  TPP  conjugate,  MitoSNO  (Figure  1c),  reduces  the  
production  of  ROS  by  inhibiting  the  mechanism  of  ROS  generation  (32).  In  principle,  
this   is  a  more  efficacious  approach  because  MitoSNO  stoichiometrically  inhibits  the  
catalytic  generation  of  ROS  by  the  ETC,  so  that  each  molecule  of  MitoSNO  prevents  
the   formation   of   many   ROS   molecules.      MitoSNO   limits   the   damage   caused   by  
myocardial  infarction   in  vivo  by  nitrosating  Cys39  on  the  ND3  subunit  of  complex  I  
of  the  ETC  (33).  The  nitrosation  is  reversible,  but  inhibits  the  ETC  during  reperfusion,  
so   minimizing   the   production   of   the   ROS   responsible   for   reperfusion   injury.  
Importantly,   the   protein   thiol   target   is   only   exposed   under   anoxia:   this   gives  
selectivity   for   affecting   dysfunctional   mitochondria   in   the   presence   of   functional  
mitochondria  in  other  tissues.      
MitoSNO  acts  directly  on   its   target,  which   is   exposed  during   ischemia.     An  
alternative   approach   would   be   to   control   the   release   of   a   drug   so   that   it   is   only  
present   in  dysfunctional  mitochondria.  Selectivity  would   then  be  achieved   through  
activation   of   a   prodrug   by   processes   associated   with   dysfunctional   mitochondria.    
MitoDNP-­‐‑SUM  is  a  prototypical  example  of  such  a  prodrug  (Figures  1d  and  3c)  (17).  
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ROS  are  generated  when   the  potential  across   the  MIM  is  elevated.     MitoDNP-­‐‑SUM  
accumulates   in   all   mitochondria   in   accordance   with   the   Nernst   equation,   and   is  
activated   by   hydrogen   peroxide   to   release   the   proton-­‐‑translocator,   DNP.      Proton  
translocation   across   the   MIM   is   known   to   reduce   the   membrane   potential.      In  
principle,  this  provides  a  negative  feedback  as  mitochondria  with  lower  memberane  
potentials   produce   fewer   ROS   and   even   a   small   drop   in   the   membrane   potential  
leads  to  a  large  drop  in  ROS  production.    The  release  of  DNP  from  MitoDNP-­‐‑SUM  is  
mediated   by   the   reaction   between   the   hydroperoxide   anion   and   the   arylboronate  
unit   (Figure   6)   (17,34).   This   produces   a   phenoxide   intermediate,   which   then  
fragments   to   release  DNP–   and   a   quinone  methide,  which   rapidly   reacts   to   give   a  
benzylic  alcohol  side  product.  
  
1.2  Mitochondria-­‐‑targeted  sensors  
Mitochondrial  ROS  appear   to  be   important   to  a  wide   range  of  diseases  and  
are   central   to   the   free   radical   theory   of   aging.      Furthermore,   there   is   growing  
evidence  that  different  ROS  have  different  effects,  and  that  these  effects  are  location  
and   concentration   dependent   (35).   Therefore,   a   range   of   mitochondria-­‐‑targeted  
sensors  have  been  reported  (Figure  7).    Nitrone  spin  traps  have  been  made  that  react  
with   the   highly   reactive   radicals   involved   in   oxidative   stress   to   give   longer   lived  
nitroxyl   radicals   that   can   be   detected   by   EPR   spectrometry,   e.g.   MitoPBN   (36),  
MitoSpin   (37),   MitoBMPO   (38)   and   MitoDEPMPO   (Figure   7a)   (39,40).   Often,   the  
hyperfine  couplings  allow  the  type  of  radical  trapped  to  be  identified.  The  adducts  of  
oxygen-­‐‑centred   radicals   are   generally   short-­‐‑lived,   and   superoxide   adducts   are  
particularly   unstable.      However,   MitoBMPO   and   MitoDEPMPO   produce   distinct,  
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detectable   superoxide   adducts   (38-­‐‑40).   Unfortunately,   high   concentrations   of   the  
traps  are  necessary  making  in  vivo  work  impractical.      
An   alternative   is   to   detect   ROS   using   fluorescence   (41).   Superoxide   can   be  
detected   by   Mito-­‐‑HE   (commercially   called   MitoSOXTM   red,   Figure   7b)   (42),   an  
analogue   of   hydroethidine   targeted   to   the   mitochondria   by   TPP,   gives   a   specific  
hydroxylated   N-­‐‑alkylphenanthridinium   salt,   HO-­‐‑Mito-­‐‑Etd+,   upon   reaction   with  
superoxide.      The   product   can   be   detected   using   its   fluorescence   at   579   nm   when  
excited   at   510   nm,   or   by   excitation   at   396   nm.      Exciting   at   396   nm   minimises  
confusion   arising   from   other   phenanthridinium   cations   produced   by   non-­‐‑specific  
oxidation.  The  detection  method  relies  on  the  fluorescence  enhancement  that  occurs  
when   the   phenanthridinium   cations   intercalates   into   DNA.      Since   other  
phenanthridinium  cations  also  fluoresce,  efforts  have  been  made  to  distinguish  and  
quantify   the   products   of   hydroethidine   oxidation   by   HPLC   (43).   However,   the  
interaction   with   DNA   is   problematic   as   it   can   hamper   extraction   of   the  
phenanthridinium  cations   and   could   lead   to   off-­‐‑target   effects   resulting   in   artefacts.    
Current   efforts   are   focussing   on   developing   synthetic   methods   (44)   to   access  
hydroethidine  analogues  that  are  oxidized  to  hydroxyphenanthridinium  cations  that  
do  not  interact  with  DNA.  
The   specific   reaction   between   an   arylboronate   and   hydrogen   peroxide   or  
peroxynitrite   to   give   a   phenol   has   been   used   as   an   on-­‐‑switch   for   a  mitochondria-­‐‑
targeted  pre-­‐‑fluorophore,  MitoPy1  (Figure  7b)  (45,46).  The  reaction  is  irreversible,  so  
the  rate  of  increase  of  fluorescence  indicates  the  concentration  of  hydrogen  peroxide  
present.    Fluorescent  probes  are  easy  to  use  in  cell-­‐‑based  studies,  but  are  less  useful  
in   whole   organisms   due   to   autofluorescence   and   limited   light   penetration.      One  
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solution  is  to  express  luciferase  in  an  organism  and  then  use  a  so-­‐‑called  peroxy  caged  
luciferin   (e.g.   PCL-­‐‑2)   (47,48),   which   is   uncaged   by   hydrogen   peroxide   by   the  
mechanism   discussed   above.   The   luciferin   then   undergoes   a   chemoluminescent  
reaction  catalysed  by  the  expressed  luciferase  leading  to  emission  of  light  in  response  
to  hydrogen  peroxide.     However,   there   is  no  mitochondria-­‐‑targeted  version  of   this  
compound  yet.    
In  summary,  the  lack  of  effective  methods  of  detecting  specific  mitochondrial  
ROS  in  vivo  had  meant  that  surprisingly  little  was  known  about  the  concentrations  
of   these   species   in  whole   living   organisms.      Indeed,   there  was   no  method   for   the  
direct   determination   of   how   mitochondrial   ROS   varies   with   age   and   with  
interventions  that  affect  the  rate  of  ageing.    This  was  a  serious  short-­‐‑coming  as  ROS  
are   implicated   in  almost  all   the  diseases  of  older  age  and   the   free   radical   theory  of  
aging  rests  on  the  proposal  that  damage  from  mitochondrial  ROS  accumulates  with  
age.     We  recently  disclosed  that  a  mitochondria-­‐‑targeted  arylboronate  MitoB  can  be  
used  to  determine  directly  changes   in   the  concentration  of  mitochondrial  hydrogen  
peroxide  in  whole  organisms  (Figure  7c)  (49,50).  We  have  reported  the  use  of  MitoB  
in  living  flies  (Drosophila  melanogaster),  nematodes  (Caenorhabditis  elegans),  and  mice,  
including   providing   a   detailed   step   by   step   protocol   (33,49,50),   and   are   now  
investigating  its  application  to  fish.    Since  these  reports  include  detailed  descriptions  
of  how  MitoB  is  employed,  we  will  only  provide  a  very  brief  overview  of  the  main  
features  of  this  probe.    On  the  other  hand,  we  report  here  a  detailed  protocol  for  the  
synthesis  and  purification  of  MitoB  and  all  the  chemical  standards  needed  for  its  use.    
MitoB   has   a   TPP   group   that   causes   it   to   accumulate   in   mitochondria.    
Following   injection   into   the   organism,   MitoB   rapidly   distributes   to   the   various  
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tissues  of  the  body  so  that  about  90%  of  the  probe  is  intracellular  and  98%  of  this  is  
within  the  mitochondria.    It  reacts  with  hydrogen  peroxide  to  give  the  phenol,  MitoP  
(Figure  8).     More  precisely,   it   reacts  with   the  conjugate  base  of  hydrogen  peroxide,  
the  hydroperoxide  anion,  so  that  the  higher  pH  of  the  mitochondrial  matrix  gives  an  
additional   four-­‐‑fold   acceleration   relative   to   reaction   in   the   cytosol.      With   the  
exception  of  peroxynitrite  and  HOCl,  other  ROS  do  not  react  with  MitoB  to  give  this  
product   (51,52).   Importantly,   the   rate   constant   for   reaction   between   the  
mitochondrial  peroxidase,  peroxiredoxin  III,  and  hydrogen  peroxide  is  over  a  million  
times  higher  than  that  for  reaction  with  MitoB  (49).  Since  MitoB  reacts  slowly,  it  does  
not  itself  influence  the  hydrogen  peroxide  concentration.    
Both  MitoB  and  MitoP  can  be  easily  detected  by  electrospray  ionization  mass  
spectrometry  (ESI-­‐‑MS)  with  high  sensitivity,  because  each  molecule  already  bears  a  
fixed  positive   charge  and  does  not  need   to  be   ionized   to  be  detected.     As  MitoB   is  
converted   irreversibly   into  MitoP,   the   ratio   of  MitoP   to  MitoB   increases  with   time.    
The   rate   of   this   increase   reflects   the   concentration   of   hydrogen   peroxide.      The  
concentration   of   MitoB   in   the   mitochondrial   matrix   is   about   3000   times   the  
extracellular   concentration,   and   this   combined  with  higher  proportion  of  hydrogen  
peroxide   in   its   deprotonated   form   means   that   MitoP   production   occurs   almost  
exclusively  in  the  mitochondrial  matrix.    Expressing  the  amount  of  MitoP  and  MitoB  
as  a  ratio  corrects  for  absolute  concentration.      
To   date,   we   have   determined   the   ratio   of   MitoP   to   MitoB   following  
euthanasing  the  animals,  but  in  principle  the  ratio  of  MitoP  to  MitoB  in  fluids  such  as  
blood   or   urine   might   be   used   to   monitor   hydrogen   peroxide   concentrations  
continuously   because   both   MitoP   and   MitoB   freely   diffuse   in   and   out   of  
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mitochondria.    However,  in  all  cases  quantification  requires  correction  for  extraction  
efficiency.     This   is  done  by  adding  a  known  quantity  of  d15-­‐‑MitoB  and  deuterated  
d15-­‐‑MitoP  after   the  experiment   is   complete  and  before  extraction  of   the  MitoB  and  
MitoP.      For   convenience   both   deutero   standards   are   prepared   from   perdeutero  
triphenylphosphine  so   there  are  15   labels   in  each.     Thus,   the  amount  of  MitoP   (m/z  
369)   is   determined   by   comparison   with   d15-­‐‑MitoP   (m/z   384),   and   the   amount   of  
MitoB   (m/z   397)   is   determined   relative   to   d15-­‐‑MitoB   (m/z   412).      Liquid  
chromatography   (LC)   is   used   to   separate   the   TPP   compounds   from   other  
endogenous  compounds  extracted  with  them.    Often  the  TPP  compounds  elute  at  the  
same  time,  and  the  compounds  are  detected  simultaneously  using  multiple  reaction  
monitoring   [for   details   of   this   and   the   comparison  with   the   deutero   standards   see  
Cochemé   et   al.   (49,50)].     Depending  on   the  LC   system  used,   there  may  be   some  or  
complete   separation   of   MitoB   from   MitoP,   and   indeed   partial   separation   of   the  
deutero   labelled   and  unlabelled   version   of   the   compounds   is   also   possible   (53-­‐‑55).  
Therefore,   it   is   important   to   sample   the   ions   over   the   whole   peak   so   that   the  
proportions  are  correct.    
MitoP   is   an   exomarker   (56)   of   mitochondrial   hydrogen   peroxide   in   living  
organisms   (Figure  9).     This   is   similar   to  a  biomarker,  but   is  produced  by  a   specific  
transformation  of  an  exogenous  probe,  in  this  case  MitoB.    Whereas  biomarkers  may  
be   produced   by   a   range   of   processes,   a   small   molecule   probe   can   be   designed   to  
detect   a   specific   endogenous   compound,   in   this   case   hydrogen   peroxide,   in   a  
particular  place,  e.g.  the  mitochondria.    Exomarkers  have  the  advantage  that  they  are  
neither   produced   nor   degraded   by   endogenous   processes   and   so   reflect   more  
accurately   the   concentration   of   the   species   they   are   designed   to   detect.      An  
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exomarker   approach   to   the   detection   of   mitochondrial   glyoxal   and   methylglyoxal  
has  also  been  developed  using  MitoG  (Figure  7c)  (57).    
Detailed  protocols   for   the  preparation  of  MitoB,  d15-­‐‑MitoB,  MitoP  and  d15-­‐‑




2.1  Equipment  for  Synthesis    
1. UV  lamp  (to  check  TLC  plates,  254  nm)  
2. Oven  (200  °C+  capable)  
3. Fridge  (0  -­‐‑  5  °C  capable)  
4. Stirring/heating  plate  with  temperature  probe  
5. Oil  bath  or  alternative  heating  media  
6. Rotary  evaporator  (in    fume  hood)  attached  to  vacuum  line  
7. Vacuum  pump  (weak  vacuum,  100  mbar  sufficient)  
8. Vacuum  line  (<20  mbar)  
9. Inert   gas   supply   (approximately   atmospheric   pressure,   balloon   sufficient),  
attached  to  a  short  needle  
10. Dewar-­‐‑type  bowl  (large  enough  for  the  50  mL  flask  and  coolant)  
11. Thermometer  (effective  down  to  at  least  −20  °C)  
12. Desiccator  
13. 1  x  clamp  stand  and  appropriate  clamps  
14. 2  x  50  mL  round  bottomed  flask  
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15. 3  x  100  mL  round  bottomed  flask  
16. 2  x  250  mL  round  bottomed  flask  
17. 1  x  condenser  (appropriate  to  fit  flask)  and  connections  to  attach  water  
18. 5  x  suba  seals  to  fit  condenser  and  flasks  
19. 2  x  Magnetic  stirrer  bar  
20. 100  or  greater  mL  Buchner  flask  and  small  buchner  funnel  with  filter  paper  or  
equivalent  filtration  set  up  
21. 1  L  or  greater  mL  Buchner  flask  and  large  (500  mL)  buchner  funnel  with  filter  
paper  or  equivalent  filtration  set  up  
22. 50  mL  beaker  
23. 2  x  1  L  beaker  or  conical  flask  
24. Appropriate  sample  vials  (10  mL)  
25. Glass  pipettes  and  pipette  teats  
26. 1  mL  syringes  and  appropriate  needles  
27. 2  x  20  mL  syringe  
28. 1  x  50  mL  syringe  
29. 4  x  long  metal  needle  
30. Chromatography  grade  silica  gel  (SiO2)  and  acidified  sand  
31. 2  x  TLC  plates  and  appropriate  tank  
32. NMR  tube  and  access  to  NMR  machine  
  
2.2  Synthesis  of  MitoB    
1. Toluene  (irritant,  health  hazard,  flammable)  
2. Triphenylphosphine  (harmful,  health  hazard)  
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3. (3-­‐‑bromomethyl)phenylboronic  acid  (irritant)  
4. dimethyl  sulfoxide  (irritant)  
5. Distilled  water  
6. Diethyl  ether  (flammable,  harmful)  
7. d6-­‐‑dimethyl  sulfoxide  (irritant)  
  
2.3  Synthesis  of  d15-­‐‑MitoB  
The   same   materials   as   for   MitoB,   except   replace   triphenylphosphine   with   d15-­‐‑
triphenylphosphine.  
  
2.4  Synthesis  of  MitoP  
1. 3-­‐‑hydroxymethylbenzylalcohol  (harmful/irritant,  corrosive)  
2. Phosphorus   tribromide   (1   M   solution   in   dichloromethane,   corrosive,  
harmful/irritant)  
3. Anhydrous  pyridine  (harmful/irritant,  flammable)  
4. Anhydrous  acetonitrile  (harmful/irritant,  flammable)  
5. Anhydrous  toluene  (irritant,  health  hazard,  flammable)  
6. Triphenylphosphine  (harmful,  health  hazard)  
7. Ethyl  acetate  (irritant,  flammable)  
8. Diethyl  ether  (harmful,  flammable)  
9. Dichloromethane  (harmful,  health  hazard)  
10. Ethanol  (flammable)  
11. Distilled  water  
12. Dry  ice  (CO2(s),  may  cause  burns,  CO2(g)  hazardous  above  1.5%  concentration)  
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13. Acetone  or  2-­‐‑isopropanol  (flammable,  irritant)  
14. d6-­‐‑dimethyl  sulfoxide  
15. Magnesium  Sulfate  
  
2.5  Synthesis  of  d15-­‐‑MitoP  





3.1  Overview  of  procedure  for  the  synthesis  of  MitoB  and  d15-­‐‑MitoB  
   MitoB   was   prepared   from   commercially   available   3-­‐‑
(bromomethyl)phenylboronic  acid  using  triphenylphosphine  to  displace  the  benzylic  
bromide   (Figure   10).      The   procedure   produces   the   bromide   salt   (MW   477.14).   The  
reaction   is   carried   out   in   boiling   toluene   under   reflux   and   the   MitoB   bromide  
precipitates   from   solution.      The   solid  MitoB   bromide   is   collected   by   filtration   and  
then  recrystallized  from  DMSO.    MitoB  is  an  arylboronic  acid  and  can  dehydrate  to  
form  a   trimer,  so  a   final   recrystallization   from  water   is  carried  out   to  ensure  MitoB  
bromide   is   entirely   in   the   boronic   acid   form.      d15-­‐‑MitoB   bromide   is   prepared   in  
exactly   the   same   way   except   d15-­‐‑triphenylphosphine   is   used   instead   of  
triphenylphosphine.  
  
3.2  Setup  for  preparation  of  MitoB  and  d15-­‐‑MitoB    (see  Note  1)  
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1. For   the   preparation   of   MitoB,   weigh   out   1.00   g   (4.65   mmol,   1.00   eq.)   3-­‐‑
(bromomethyl)phenylboronic   acid   and   1.34   g   (5.11   mmol,   1.10   eq.)  
triphenylphosphine   and   add   both   to   the   50   mL   round   bottomed   flask  
containing   the   magnetic   stirrer   bar   (see   Note   2).   Alternatively,   for   the  
preparation   of   d15-­‐‑MitoB,   weigh   out   1.00   g   3-­‐‑(bromomethyl)phenylboronic  
acid   and   1.42   g   d15-­‐‑triphenylphosphine   and   add   both   to   the   50  mL   round  
bottomed  flask.  
2. Clamp  the  flask  around  the  ground  glass  joint  to  the  clamp  stand,  arranged  so  
it   is   centrally   positioned   in   the   heating  medium   on   top   of   the   stirrer   plate.  
Add  25  mL  toluene.  
3. Attach  the  condenser  to  the  flask,  adding  a  suba  seal  and  inert  gas  inlet  to  the  
top  of  the  condenser  by  way  of  a  needle  piercing  the  suba  seal.  Attach  water  
supply  to  the  condenser.  
4. Insert  a  second  needle  in  the  suba  seal  to  act  as  an  outlet  and  purge  the  flask  
and  condenser  with  the  inert  gas  for  5  min.  
5. Start  the  stirring  and  then  set  the  reaction  to  heat  to  reflux.    The  boiling  point  
of  toluene  is  110-­‐‑111  °C.  
6. When  the  boiling  temperature  is  reached,  continue  to  heat  the  reaction  under  
reflux   for   6   h   for   complete   conversion   to   product,   which   precipitates   as   a  
solid  (see  Note  2  ).  
7. Turn  off  heat  and  remove  the  reaction  from  the  heat  source  by  moving  clamp  
arm  bearing  the  flask  upward.  Allow  to  cool   for  30  min.  Meanwhile  heat  20  
mL  toluene  to  70  °C  in  the  100  mL  round  bottomed  flask.  
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8. Filter  under  vacuum  to  collect  the  solid  MitoB  bromide.    Re-­‐‑use  the  filtrate  to  
wash  out  the  contents  of  the  round  bottomed  flask  pouring  the  washings  over  
the   filter   cake   of   MitoB   bromide.      Wash   out   the   flask   twice   with   the   hot  
toluene   (10  mL  each  wash,  preheated   to  70   °C)  again  pouring   the  washings  
over   the   filter  cake  of  MitoB  bromide.     Finally  wash   the   filter  cake   followed  
with  30  mL  diethyl  ether.  Allow  the  material  to  further  dry  under  vacuum  for  
20  min.  
  
3.3  Purification  of  MitoB  
1. Add   approximately   500   mg   of   solid   crude   MitoB   bromide   to   0.7   mL   of  
dimethyl  sulfoxide  and  heat  to  dissolve  in  a  sample  vial.  Allow  the  material  
to  cool,  crystallize  and  settle  (1  h)  (see  Note  3).  
2. Carefully   remove   the   dimethyl   sulfoxide   with   a   pipette   (leave   the   crystals  
behind).  
3. Repeat   steps   1   and   2   with   more   solid   crude   MitoB   bromide,   reusing   the  
dimethyl   sulfoxide   from   the   previous   crystallisation   (see   Note   4)   and   an  
additional   0.1   mL   (measured   with   a   1   mL   syringe   and   used   to   wash   the  
residual  material  through  the  empty  pipette  following  transfer)  until  all  crude  
material   has   been   recrystallized   (you   will   now   have   up   to   five   vials   each  
containing  approximately  400  mg  recrystallized  material).    
4. After  removing  the  dimethyl  sulfoxide  from  each  sample  vial,  add  1.5  mL  of  
hot  distilled  water,  agitate  and  allow  to  settle  before  carefully   removing   the  
liquid  with  a  pipette,   leaving   the   solid  MitoB  bromide   in   the  vial.  Combine  
these  waste   aqueous   solutions   and   the   final  waste   dimethyl   sulfoxide,   then  
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collect   any   further   crystals   formed,   retrieving   the   final   batch   of   crystals   by  
vacuum  filtration  if  necessary,  re-­‐‑using  the  previously  mentioned  apparatus.  
5. Combine   the   batches   of   crystallized  MitoB   bromide   in   a   100   or   greater  mL  
round  bottomed  flask,  using  hot  distilled  water  in  1  mL  aliquots  to  wash  any  
residual  solid  into  the  flask.  
6. Add  distilled  water  to  a  volume  of  40-­‐‑50  mL  and  heat  to  80  °C  on  the  rotary  
evaporator  at  ambient  pressure  for  1  h,  then  allow  the  heating  bath  to  cool  to  
50  °C  and  carefully  concentrate  the  water  under  vacuum  until  a  white  solid  is  
observed  forming  on  the  flask  walls  (see  Note  5).  
7. When   solid   is   observed,   remove   the   flask   and   allow   it   to   cool.      The  MitoB  
bromide  continues  to  precipitate  from  solution.    Collect  the  solid  by  filtering  
under   vacuum   as   previously,   allowing   30   min-­‐‑1   h   (depending   on   vacuum  
strength)  to  dry  the  solid  material.  The  filtrate  can  be  reused  to  obtain  more  
MitoB  bromide  if  desired,  by  further  concentrating  as  in  step  5.  
8. Collect  the  material  in  a  pre-­‐‑weighed  vial  and  check  purity  (if  possible)  by  1H  
NMR   in   d6-­‐‑dimethyl   sulfoxide,   with   approx.   2   mg   of   material   in   a   0.5   mL  
sample  (see  Note  6).  
  
Approximate  Yield:  70%  
  
3.4  Characterization  data  for  MitoB  
δH   (500  MHz,   d6–dimethyl   sulfoxide):   7.95   [2H,   s,   B(OH)2],   7.92-­‐‑7.86   (3H,  m,   3   x   p-­‐‑
PPh3),  7.77-­‐‑7.68  (7H,  m,  6  x  o-­‐‑PPh3,  H4),  7.67-­‐‑7.58  (6H,  6  x  m-­‐‑PPh3),  7.46  (1H,  s,  H2),  
7.18  (1H,  t,  J  =  7.6  Hz,  H5),  6.94  (1H,  d,  J  =  7.6  Hz,  H6),  5.11  (2H,  J  =  15.6  Hz,  CH2Ph).  
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δC  (100  MHz,  d6–dimethyl  sulfoxide):  136.88  (d,  J  =  5.6  Hz,  CH),  134.94  (d,  J  =  2.4  Hz,  
CH),  133.93  (d,  J  =  9.8  Hz,  CH),  133.78  (d,  J  =  3.6  Hz,  CH),  132.25  (d,  J  =  5.2  Hz,  CH),  
129.95  (d,  J  =  12.5  Hz,  CH),  127.60  (d,  J  =  2.8  Hz,  CH),  126.67  (d,  J  =  8.5  Hz,  C),  117.75  
(d,  J  =  85.5  Hz,  C),  28.15  (d,  J  =  46.5  Hz,  CH2).    
δP  (162  MHz,  d6–dimethyl  sulfoxide)  23.15  (s).    
IR   (ATR,   cm–1):   3322   (OH),   2928   (ArH,   v.  weak),   2882   (ArH),   2789   (ArH,   v.  weak),  
1549   (Ar,   v.   weak),   1485   (Ar,   weak),   1435   (Ar,   strong).   LRMS   (ESI):   397   [M+  
(phosphonium  cation),  100%].    
HRMS:  397.1518  [M+  (phosphonium  cation)].  C25H2311BO2P  requires  397.1524.    
Microanalysis:  C25H23BBrO2P  requires  C:  62.93%  H:  4.86%,  found  C:  62.90%  H:  4.80%.  
  
3.5  Characterization  data  for  d15-­‐‑MitoB:  
δH  (400  MHz,  d6–dimethyl  sulfoxide):  92:8  mixture  of  d15:d14:  7.97  [2H,  s,  B(OH)2],  7.74-­‐‑
7.69  (1H,  m,  H4),  7.46  (1H,  s,  H2),  7.17  (1H,  t,  J  =  7.6  Hz,  H5),  6.94  (1H,  d,  J  =  7.6  Hz,  
H6),  5.12  (2H,  J  =  15.6  Hz,  CH2Ph).  δC  (100  MHz,  d6–dimethyl  sulfoxide):  137.02  (d,  J  =  
5.6  Hz,  CH),  135.08-­‐‑134.22  (m,  CD),  133.92  (d,  J  =  2.7  Hz,  CH),  134.22-­‐‑133.12  (m,  CD),  
132.43  (d,  J  =  5.5  Hz,  CH),  130.05-­‐‑129.15  (m,  CD),  127.75  (d,  J  =  2.6  Hz,  CH),  126.84  (d,  
J  =  8.6  Hz,  C),  117.67  (d,  J  =  85.4  Hz,  C),  28.27  (d,  J  =  46.5  Hz,  CH2).  δP  (162  MHz,  d6–
dimethyl  sulfoxide):  23.01  (s).   IR  (ATR,  cm–1):  3236  (OH),  2928  (ArH,  v.  weak),  2882  
(ArH),   1543   (Ar),   1485   (Ar),   1424   (Ar,   moderately   strong).   LRMS   (ESI):   412  
[M+(phosphoniumcation),   100%].   HRMS:   412.2460   [M+(phosphonium   cation)].  
C25H2311BO2P  requires  412.2465.  Microanalysis:  C25H8D15BBrO2P  requires  C:  61.00%  H:  
1.64%  D:  6.14%,  found  C:  60.90%  H:  1.64%  D:  6.17%.  
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d14  peaks  observed:  δH  (400  MHz,  d6–dimethyl  sulfoxide):  7.89  (0.02H,  d,  J  =  2.0  Hz,  p-­‐‑
PPh3),  7.63  (0.03H,  d,  J  =  12.7  Hz,  o-­‐‑PPh3),  7.24  (0.03H,  d,  J  =  8.0  Hz,  m-­‐‑PPh3).  
  
3.6  Overview  of  procedure  for  the  synthesis  of  MitoP  and  d15-­‐‑MitoP  (see  Note  7)  
   MitoP  is  prepared  in  two  steps  by  an  adaptation  of  the  procedure  described  
by  Dawson   et   al.   (58)   (Figure   11).      First,   in   reaction  A,   3-­‐‑hydroxybenzyl   alcohol   is  
converted   into   the  3-­‐‑(bromomethyl)phenol  by  reaction  with  phosphorus   tribromide  
in   a   mixture   of   anhydrous   pyridine   and   anhydrous   acetonitrile.      The   reaction   is  
water-­‐‑sensitive   and   phosphorus   tribromide   reacts   violently   with   water.   3-­‐‑
(Bromomethyl)phenol   is  a  reactive  compound  and  should  be  used  for  the  next  step  
soon  after  preparation.    The  second  step,  reaction  B,  involves  displacing  the  benzylic  
bromide  with  triphenylphosphine  to  give  MitoP  bromide.    The  reaction  is  carried  out  
in  boiling  toluene  under  reflux  and  MitoP  bromide  precipitates  from  solution.    Often  
the   MitoP   is   essentially   pure   after   work-­‐‑up,   but   recrystallization   from   ethanol   is  
possible   if   impure  material   is   obtained.      d15-­‐‑MitoP   bromide   is   prepared   by   using  
d15-­‐‑triphenylphosphine  instead  of  triphenylphosphine  in  reaction  B.  
  
3.7  Setting  up  reaction  A  
1. Dry   one   50   mL   and   two   100   mL   round   bottomed   flasks   and   appropriate  
stirrer   bars,   the  metal   needles   and   the   condenser   overnight   in   a  dry   250   °C  
oven.  Alternatively,  the  flasks  can  be  dried  under  vacuum  with  a  heat  gun  or  
Bunsen   burner   (do   not   do   this   with   the   condenser).   The   dry   glassware,  
needles  and  stirrer  bars  should  be  allowed  to  cool  under  vacuum  and  kept  in  
a  sealed  dessicator  prior  to  use.  
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2. Prepare  a  -­‐‑15  °C  bath  on  a  stirrer  plate  by  adding  dry  ice  to  2-­‐‑isopropanol  or  
acetone   in   a   dewar,   checking   with   a   thermometer.   Err   on   the   cold   side:  
somewhat   below   -­‐‑15   °C   is   acceptable,   but   above   this   temperature   is   not  
satisfactory.  (see  Note  8).  
3. Attach   anhydrous   acetonitrile,   phosphorus   tribromide   solution   and  
anhydrous  pyridine  to  an  inert  gas  supply.  
4. Set  up  the  50  mL  flask  in  the  dewar,  sealing  with  a  suba  seal  and  connecting  
to  inert  gas.  
  
3.8  Reaction  A  
1. Add  14.1  mL  phosphorus  tribromide  solution  and  5  mL  acetonitrile  to  a  100  
mL   round  bottomed   flask  using   long  needles   attached   to   syringes,   then   stir  
the  mixture.  Immediately  return  the  acetonitrile  needle  and  syringe  to  a  dry,  
inert   environment   for   later  use   (putting   the  needle  back   through  a   seal   into  
the  dry  solvent  container  with  the  syringe  still  attached  is  sufficient).  Quench  
the   phosphorus   tribromide   needle   into   20  mL   dichloromethane   then   add   5  
mL  ethanol  to  this  solution.  Dispose  of  this  as  toxic  waste.  
2. Add  0.75  mL  anhydrous  pyridine  dropwise   over   10  min  with   a  needle   and  
syringe  to  the  stirring  mixture  (see  Note  9).  
3. Dissolve  5  g  3-­‐‑hydroxymethylbenzyl  alcohol  in  15  mL  anhydrous  acetonitrile  
and  0.25  mL  anhydrous  pyridine  in  a  50  mL  round  bottomed  flask  (see  Note  
10),  then  add  the  solution  to  the  reaction  mixture  dropwise  over  10  min  using  
a  long  needle  and  20  mL  syringe.  An  additional  2  mL  anhydrous  acetonitrile  
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can   then   be   used   to   wash   any   residual   material   from   the   50   mL   round  
bottomed  flask  into  the  reaction  mixture.  
4. Allow  the  reaction  to  stir  and  warm  gradually  to  room  temperature  over  4  h.  
  
3.9  Workup  of  Reaction  A  (see  Note  11)  
1. Prepare  2  L  19:1  dichloromethane/ethyl  acetate.    
2. Use  300  mL  of  this  solution  to  make  a  slurry  with  approximately  250  mL  SiO2  
in  a  1  L  beaker  or  conical  flask,  then  load  this  into  the  large  Buchner  funnel.  
Allow  the  solvent  to  run  through  to  incipient  wetness,  agitating  gently  to  aid  
silica  settling,  then  top  with  a  1  cm  layer  of  acidified  sand.  
3. Transfer   the   reaction  mixture   from  reaction  A   to  a   250  mL   round  bottomed  
flask,   washing   the   residue   in   with   dichloromethane   (see   Note   12),   then  
remove  the  solvent  under  reduced  pressure  in  a  fume  hood,  disposing  of  the  
distillate  as  toxic  waste.  
4. Dissolve   the   residue   in   100   mL   dichloromethane,   then   wash   with   100   mL  
H2O,  re-­‐‑extracting  with  a  further  100  mL  dichloromethane  (see  Note  11).  
5. Add   the   combined   dichloromethane   solutions   to   the   silica   in   the   Buchner  
funnel,  allowing  the  solvent  to  run  through  under  atmospheric  pressure  until  
no   residual   solvent   remains   above   the   silica   layer,   discarding   the   resulting  
filtrate.   Add   1   cm   sand   and   elute   the   compound   under   vacuum   with   the  
dichloromethane/ethyl  acetate  solution,  collecting  fractions  of  approximately  
300  mL   (see  Note   13),   then   spotting   each   on   a   silica   TLC   plate   in   turn   and  
stopping  when   the   last   fraction  shows  no  UV  activity  under  an  appropriate  
lamp.   Confirm   the   product   fractions   by   TLC   (Rf   =   0.57   in   9:1  
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dichloromethane/ethyl  acetate)  and  combine  these   in  a  1  L  beaker  or  conical  
flask.  
6. Add  magnesium  sulfate  to  the  filtrate  and  swirl,  then  filter  the  solution,  using  
dichloromethane  to  wash  any  residual  material  from  the  magnesium  sulfate.  
7. Half   fill   a  250  mL  round  bottomed   flask  with  a  portion  of   the   solution,  and  
remove   the   solvent   under   reduced   pressure,   add   a   further   portion   of   the  
solution   and   repeat   until   all   the   material   is   contained   in   the   flask   and   all  
solvent  has  been  removed.  
  
3.10  Characterization  data  for  3-­‐‑(bromomethyl)phenol:  
δH  (500  MHz,  CDCl3):  7.21  (1H,  t,  J  =  7.9  Hz,  H5)  6.97  (1H,  d,  broad,  J  =  7.7  Hz,  H4),    
6.88  (1H,  t,  J  =  2.1  Hz,  H2),  6.77  (1H,  ddd,  J  =  8.1,  2.5,  0.7  Hz,  H6),  4.44  (2H,  s,  CH2).  δC  
(100   MHz,   CDCl3):   155.75   (C),   139.56   (C),   120.20   (CH),   121.63   (CH),   116.07   (CH),  
115.69   (CH),   33.27   (CH2).   IR   (ATR  cm-­‐‑1):   3354   (O-­‐‑H),   1591   (CAr=CAr),   1489   (CAr=CAr),  
1456  (CAr=CAr).  LRMS  (EI+):  187.99  (81BrM+.,  31%),  185.99  (81BrM+.,  33%),  107.06  [(M+  −  
Br),  100%].  HRMS:  187.9652  and  185.9686.  C7H7OBr  requires  187.9660  and  185.9680.  
MP:  60  -­‐‑  63  °C.  
  
3.11  Setting  up  reaction  B  
1. Add  70  mL  dry  toluene,  a  suitable  stirrer  bar  and  10  g  triphenylphosphine  to  
the  reaction  A  product.  
2. Attach  the  condenser  to  the  water  and  round  bottomed  flask;  put  under  inert  
gas  and  heat  to  reflux  while  stirring  for  6  h.  
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3.12  Work  up  of  reaction  B  
1. Warm  100  mL  toluene  to  70  °C  in  a  250  mL  round  bottomed  flask.  
2. Filter   the   reaction   mixture   vacuum,   re-­‐‑using   the   filtrate   to   wash   out   the  
contents  of  the  flask,  then  wash  out  the  flask  with  a  further  2  x  50  mL  70  °C  
toluene   and   use   these   to   further   wash   the   filter   cake,   followed   by   100   mL  
diethyl  ether.  Allow  the  material  to  further  dry  under  vacuum  for  20  min.  
3. Check   purity   by   1H  NMR   in   d6-­‐‑dimethyl   sulfoxide.   Proceed   to   Section   3.13  
only  if  necessary  
  
Approximate  Yield  (2  steps):  75%  
  
3.13  Purification  (if  necessary)  
1. Add   ethanol   to   the   impure   solid   in   a   ratio   of   15   mL/g   in   a   large   round  
bottomed   flask   (100  mL   for  1  g,   see  Note  14)   then  heat   the  mixture   to  80   °C  
until  the  solid  dissolves.  
2. Remove   the   flask   from  the  heat,  allow  to  cool  and  seal  with  a  suba  seal   (see  
Note  15),  then  place  in  a  fridge  (approx.  5  °C)  for  5-­‐‑6  hours  (see  Note  16).  
3. Decant   the   solvent   from   the   crystals,   then   re-­‐‑dissolve   the   crystals   in   a  
minimal   quantity   of   warm   ethanol   and   add   distilled   water   to   reach   an  
approximate  ratio  of  2:1  ethanol/water.  
4. Carefully  remove  the  solvent  mixture  under  reduced  pressure  to  retrieve  the  
pure  solid  (see  Note  17).  
  
3.14  Characterization  data  for  MitoP  bromide  
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δH   (400   MHz,   d6–dimethyl   sulfoxide):   9.54   (1H,   s,   OH),   7.94-­‐‑7.86   (3H,   m,   3   ×   p-­‐‑H  
PPh3),  7.78-­‐‑7.70  (6H,  m,  6  ×  m-­‐‑H  PPh3),  7.70-­‐‑7.60  (6H,  m,  6  ×  o-­‐‑H  PPh3),  7.00  (1H,  t,  J  =  
7.8  Hz,  H-­‐‑5),   6.68   (1H,  broad  d,   J  =   8.0  Hz,  H-­‐‑6),   6.41   (1H,  broad   s,  H-­‐‑2),   6.36   (1H,  
broad  d,   J  =   7.1  Hz  H-­‐‑4),   5.06   (2H,  d,   J  =   15.6  Hz,  CH2).   δC   (100  MHz,  d6–dimethyl  
sulfoxide):  157.54  (d,  J  =  3.2  Hz,  C),  135.10  (d,  J  =  1.9  Hz,  CH),  134.03  (d,  J  =  9.8  Hz,  
CH),   130.11   (d,   J   =   12.5  Hz,   CH),   129.75   (d,   J   =   2.2  Hz,   CH),   129.05   (d,   J   =   8.3  Hz,  
C),121.39   (d,   J  =   5.5  Hz,  CH),   117.98   (d,   J  =   85.6  Hz,  C),   117.83   (d,   J  =   5.6  Hz,  CH),  
115.33   (d,   J   =   3.1   Hz,   CH),   28.13   (d,   J   =   46.6   Hz,   CH2).   δP   (162  MHz,   d6–dimethyl  
sulfoxide):  23.03(s).   IR  (ATR,  cm–1):  3079  (OH),  2889  (ArH),  2858  (ArH),  2787  (ArH),  
1611   (Ar),   1568(Ar).   LRMS   (ESI):   369   [M+(phosphonium   cation),   100%].  
HRMS:369.1399   [M+(phosphonium   cation)].   C25H22OP   requires   369.1403.  
Microanalysis:  C25H22BrOP  requires  C:  66.83%  H:  4.94%,  found  C:  66.89%  H:  4.98%.  
  
3.15  Characterization  data  for  d15-­‐‑MitoP  bromide  
δH   (400  MHz,  d6–dimethyl  sulfoxide):  9.55   (1H,  s,  OH),  7.00   (1H,   t,   J  =  7.8  Hz,  H-­‐‑5),  
6.69  (1H,  broad  d,  J  =  8.0Hz,  H-­‐‑6),  6.42  (1H,  broad  s,  H-­‐‑2),  6.36  (1H,  broad  d,  J  =  7.2  
Hz,  H-­‐‑4),  5.08  (2H,  d,  J  =15.7  Hz,  CH2).  δC  (100  MHz,  d6–dimethyl  sulfoxide):  157.54  
(d,   J   =   3.1  Hz,   C),   134.90-­‐‑134.23   (m,  CD),   134.08-­‐‑   133.12   (m,  CD),   130.08-­‐‑129.20   (m,  
CD),   129.73   (d,   J  =  3.4  Hz,  CH),128.57   (d,   J  =  8.6  Hz,  C),   121.39   (d,   J  =  5.6  Hz,  CH),  
117.85  (d,  J  =  5.5  Hz,  CH),  117.76  (d,  J  =  85.4  Hz,  C),  115.32  (d,  J  =  3.4  Hz,  CH),  28.16  
(d,  J  =  46.6  Hz,  CH2).  δP  (162  MHz,  d6–dimethyl  sulfoxide):  22.92  (s).  IR  (ATR,  cm–1):  
3080   (OH),   2889   (ArH),   2858   (ArH),   2787   (ArH),   1617   (Ar),   1609   (Ar),   1587   (Ar).  
LRMS   (ESI):   384   [M+(phosphonium   cation),100%].   HRMS:   384.2336   [M+  
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(phosphonium  cation)].  C25H7D15OP  requires  384.2344.  Microanalysis:  C25H7D15BrOP  




1.   Although   reasonably   dry   conditions   and   toluene   are   preferable,   use   of   all  
reagents   including   toluene   as   supplied   commercially   produces   acceptable  
results  for  this  synthesis.  
 
2.  Where  more  than  one  size  is  suitable  for  step  4,  (Section  3.2)  a  larger  stirrer  bar  
is  preferred,  as  substantial  precipitate  is  generated  and  may  impede  a  smaller  
one.  
  
3.  The  synthesis  as  outlined  does  not   require  a  centrifuge   for  Section  3.3  step  1,  
and  the  yield  given  can  be  achieved  without  one.  However,  where  available  
use  of  a  centrifuge   to  settle   the   fine  precipitate   from  the  crystallisations  will  
make  the  purification  considerably  easier.  
  
4.  Re-use of the recrystallization liquors (Section 3.3, steps 1-3) is important as 
excess dimethyl sulfoxide is relatively difficult to remove, and MitoB is fairly 
soluble in this solvent - the first 500 mg batch will saturate the solvent. 
Recrystallisation of all the material in a larger quantity of dimethyl sulfoxide 
works but has a detrimental impact on yield. 
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5.   Protodeboronation   is   possible   in   step   6   (Section   3.3);   increasing   the  
temperature  of  the  aqueous  crystallization  beyond  80  °C  appears  to  accelerate  
this   reaction.   If   this   product   is   observed,   repeating   step   6   (Section   3.3)   and  
concentrating   the   sample   less   may   be   sufficient   to   remove   this;   otherwise  
repeat  Section  3.3.  1H  NMR  of  impurity:  δH  (400  MHz,  d6–dimethyl  sulfoxide):    
7.95-­‐‑7.87  (3H,  m,  3  x  p-­‐‑PPh3),  7.79-­‐‑7.70  (6H,  m,  6  x  o-­‐‑PPh3),  7.69-­‐‑7.61  (6H,  6  x  
m-­‐‑PPh3),  7.34-­‐‑7.27  (1H,  m,  H4),  7.23  (2H,  t,  J  =  7.7  Hz,  H2,  H6),  6.99-­‐‑6.93  (2H,  
m,  H3,  H5),  5.14  (2H,  d,  J  =  15.8  Hz,  CH2Ph).  
  
6.   The   concentration   of   the   1H   NMR   sample   for   Section   3.3   step   8   is   not  
experimentally  vital,   but   is   specified   as  much   stronger   samples  will   show  a  
second   set   of   peaks   if   the   d6-­‐‑dimethyl   sulfoxide   is   dry;   these   represent  
trimerisation   of   the   boronic   acid   within   the   NMR   sample   rather   than  
degradation  of  the  material.  If  side  peaks  are  observed,  add  a  drop  of  water  to  
the  NMR  to  check  trimerisation  is  not  responsible. 
  
7.  If  possible  higher  purity  3-­‐‑hydroxymethylbenzyl  alcohol  (95%)  should  be  used,  
as   this   allows   the   compound   to   be   isolated   in   sufficient   purity   to   avoid  
recrystallization  (Section  3.6).  
  
8.  Care  should  be  taken  in  preparation  of  cold  bath  (Section  3.7,  Step  2)  not  to  add  
a   large   excess   of   dry   ice,   as   temperatures   significantly   below   the   freezing  
point  of  acetonitrile  can  be  achieved  with  such  conditions.  
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9.   Addition   of   the   pyridine   will   produce   white   gas.   Addition   of   a   vent   will  
dissipate   this,  however  positive  argon  pressure   should  be  maintained  while  
the  vent  is  in  place  (Section  3.8,  Step  1).  
  
10.  Dissolution  of   the   starting  material   is   slow   in  Section  3.8,   Step  3.   Sonication  
significantly  speeds  up  this  process.  
  
11.  Section  3.9,  and  particularly  Step  4,  should  be  performed  quickly  -­‐‑  the  product  
is  not  stable  indefinitely  and  will  react  with  water  present  to  reform  starting  
material.  Even  the  crystalline  solid  isolated  (Step  7)  may  decompose  relatively  
quickly   if   not   used,   especially   if   heated   or   impure.   For   this   reason   it   is   not  
desirable  to  heat  this  compound  strongly  to  remove  solvent  traces.  These  will  
not   interfere   with   the   following   reaction   anyway,   but   may   instead   be  
removed  under  higher  vacuum  if  desired.  
  
12.  During  Step  3  (Section  3.9)  a  significant  portion  of  the  material  will  appear  to  
be  insoluble,  however  the  desired  product  will  dissolve  in  dichloromethane.  
  
13.  Only  a  small  number  of   fractions   (5  or   less)  are  expected   for  Step  5   (Section  
3.9).  Do  not  increase  the  solvent  polarity  as  side  products  or  starting  material  
may  elute.  
  
14.   The   procedure   outlined   for   recrystallization   (Section   3.13)   uses   enough  
ethanol  to  fully  dissolve  1  g  of  Mito  P.  This  will  often  be  unnecessary  where  
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purity  is  high  (90%+)  already.  Less  ethanol  can  be  used;  it  is  not  necessary  to  
fully  dissolve  the  material  prior  to  cooling  in  these  cases.  
  
15.  Reasonable  substitutes  may  be  used  for  the  suba  seal  (Section  3.13,  Step  2);  be  
aware  however  that  warm  ethanol  vapour  will  start  to  dissolve  parafilm  and  
that   the   drop   in   temperature   on   cooling  will   result   in   a   vacuum   and  make  
glass  stoppers  difficult  to  remove.  
  
16.   In   our   experience   80%+   of   the  Mito   P  will   crystallize   out   in   the   time   given  
(Section   3.13,   Step   2),   but   it   is   likely   that   leaving   the   crystallisation   longer  
would  increase  the  yield  slightly.  
  
17.  Evaporation  in  ethanol/water  mix  is  to  remove  residual  ethanol  (Section  3.13,  
Step   4).   Care   is   required   as   ‘bumping’   is   likely   towards   the   end   of   this  
evaporation   (the   use   of   the   larger   flask   size   somewhat   mitigates   this  
problem).   In   our   experience   traces   of   ethanol   are   difficult   to   remove   from  
solid  even  with  prolonged  heating  under  vacuum.  
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Figure  1:  Example  bioactives  targeted  to  the  mitochondria  by  TPP  
  
  





































(a) Potential antioxidant drugs that react directly with ROS (some require in situ reduction to produce the active drug)
(b) Potential antioxidant drugs that catalyse the destruction of ROS












(e) Potential prodrug that depolarises mitochondrial inner membrane in response to UV light
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Figure   2:   The   accumulation   of   lipophilic   cation   conjugates   in   the   mitochondrial  
matrix  due   to   the  plasma  membrane  potential   and   the  greater  membrane  potential  
across  the  mitochondrial  inner  membrane.  
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Figure  3    Mechanism  of  accumulation  of  a  zwitterionic  TPP-­‐‑carboxylate  conjugate  in  
the  mitochondrial  matrix.  
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Figure   4:   TPP-­‐‑drug   conjugates   that   (a)   act   directly   as   drugs,   (b)   are   prodrugs   that  
release  the  drugs  in  response  to  an  instruction  from  outside  the  mitochondria,  and  (c)  
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Figure  5  ROS  and  their  generation  in  mitochondria  
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Figure   7:   Examples   of   mitochondria-­‐‑targeted   sensors   for   detecting   ROS   and   the  
products  of  oxidation  within  mitochondria  
  
  













































(a) Nitrone spin traps for detecting free radicals
(b) Probes for detecting ROS through fluorescence







Figure  8  Reaction  of  MitoB  to  produce  MitoP  
  
  


























Selective reaction with hydrogen peroxide
leads to unique change in mass
Lipophilic cation targets to 
the mitochondrion and 
easily detected by ESI-MS
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Figure   9:   The  molecular   probe,  MitoB,   is   converted   into   the   exomarker,  MitoP,   by  
reaction  with  hydrogen  peroxide  inside  the  mitochondria,  because  its  concentration  
within   these   organelles   is   approximately   3000   times   the   extracellular   concentration  
and  because  the  matrix  pH  is  about  0.8  pH  units  more  alkali   than  the  cytosol.     The  
ratio  of  MitoP/MitoB  after  a  fixed  period  reflects  the  intramitochondrial  [H2O2].  
  
  










Figure  10:  Synthesis  of  MitoB  bromide  
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